insights_auto
Why is MVIR up 2.33%?
Dive Deeperchevron_right
MVIR:STO
Medivir AB
SEKÂ 1.49
arrow_upward
+2.33%(+0.034) 1D
Oct 9, 5:29:42 PM GMT+2 · SEK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for MVIR...
Open
SEKÂ 1.47
High
SEKÂ 1.50
Low
SEKÂ 1.45
Mkt. cap
932.52M
Avg. vol.
1.41M
Volume
1.73M
52-wk high
SEKÂ 2.88
52-wk low
SEKÂ 0.34
EPS
-SEKÂ 0.37
Shares outstanding
624.18M
No. of employees
6
Open
SEKÂ 1.47
High
SEKÂ 1.50
Low
SEKÂ 1.45
Mkt. cap
932.52M
Avg. vol.
1.41M
Volume
1.73M
52-wk high
SEKÂ 2.88
52-wk low
SEKÂ 0.34
EPS
-SEKÂ 0.37
Shares outstanding
624.18M
No. of employees
6
News stories
From web sources and news partners
BigGo Finance
·
1 hour ago
Dow extends gains, climbs back above 51,300 on tech buybacks; SpaceX briefly up 3%
36Kr
·
1 hour ago
Can the US Stock Bull Market Still Continue? 2025 Outlook, Key Drivers & Future Trend Analysis
The Motley Fool
·
52 minutes ago
I've Owned the Vanguard S&P 500 ETF for 6 Years. Here's Why I'm Not Selling.
ChartMill
·
2 hours ago
These S&P500 stocks are gapping in today's session
Profile
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies.
Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
About Medivir AB